Viatris Inc (VTRS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1123)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Prossima data di guadagno

Ultimi documenti SEC

VTRS's Discussions on Twitter

Confronta VTRS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTRS Viatris Inc	11.65	13.35B	14.33B	-3.79B	1.84B	-3.17
ZTS Zoetis Inc	118.66	51.85B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	14.33	45.46B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.52	42.70B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	29.79	34.62B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	493.99	21.03B	3.08B	1.24B	1.07B	25.61

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-09	Iniziato	Barclays	Overweight
2025-10-15	Iniziato	Truist	Buy
2025-06-06	Iniziato	Goldman	Neutral
2024-07-19	Ripresa	Jefferies	Buy
2023-10-23	Downgrade	BofA Securities	Neutral → Underperform
2023-06-23	Downgrade	Barclays	Equal Weight → Underweight
2023-04-24	Downgrade	Barclays	Overweight → Equal Weight
2023-02-17	Downgrade	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Aggiornamento	Jefferies	Hold → Buy
2022-11-10	Aggiornamento	UBS	Sell → Neutral
2022-11-08	Aggiornamento	Piper Sandler	Underweight → Neutral
2022-10-21	Ripresa	Jefferies	Hold
2022-06-14	Iniziato	UBS	Sell
2022-05-10	Downgrade	Piper Sandler	Neutral → Underweight
2022-03-01	Downgrade	BofA Securities	Buy → Neutral
2022-03-01	Downgrade	Raymond James	Outperform → Mkt Perform
2021-06-15	Iniziato	Citigroup	Neutral
2021-04-07	Ripresa	RBC Capital Mkts	Outperform
2021-03-08	Downgrade	Goldman	Buy → Neutral
2021-03-02	Downgrade	JP Morgan	Overweight → Neutral
2021-02-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2021-01-05	Iniziato	Argus	Hold
2020-12-14	Iniziato	Bernstein	Mkt Perform

Mostra tutto

Viatris Inc Borsa (VTRS) Ultime notizie

Viatris Inc Azioni (VTRS) Dati Finanziari

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Confronta VTRS con altri titoli

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Borsa (VTRS) Ultime notizie

Discipline and Rules-Based Execution in VTRS Response - news.stocktradersdaily.com

Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus

How Viatris Inc stock reacts to global recession fearsJuly 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn

Viatris to Sell Entire Equity Stake in Biocon Biologics for $815 Million - Voice Of HealthCare

Barclays Initiates Coverage of Viatris (VTRS) with Overweight Recommendation - Nasdaq

Barclays Initiates Viatris at Overweight With $15 Price Target - marketscreener.com

Viatris to sell equity stake in Biocon Biologics to Biocon for $815M - MSN

Generic Drugs Market to Reach US$ 942.69 Billion by 2033 at 7.1% - openPR.com

CAM, Khaitan act on Biocon Limited acquiring stake in Biocon Biologics from Serum, Viatris - Bar and Bench

Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛

Viatris Sells Biocon Biologics Stake for $815 Million - TipRanks

Viatris Inc Announces Agreement to Monetize Biocon Biologics Stake - TradingView

Viatris to Sell its Equity Stake in Biocon Biologics for $815 Million - marketscreener.com

Viatris signs agreements with Biocon on $815m stake sale - Yahoo Finance

Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ) - Seeking Alpha

Viatris sells Biocon Biologics stake for $815 million - MSN

Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln - Nasdaq

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - PR Newswire

Biocon To Absorb Biocon Biologics, Pursue Rs 4,500 Cr QIP To Fund Viatris Payout - BW Businessworld

Biocon to absorb biologics unit, eyes Rs 4,500 cr fund raise to buy Viatris’s residual stake - Moneycontrol

Biocon integrates Biocon Biologics; to raise ₹4,500 crore via QIP to fund Viatris payout - BusinessLine

Viatris shareholders elect directors and approve proposals at annual meeting By Investing.com - Investing.com Nigeria

Viatris Holds Annual Shareholder Meeting on December 5 - TipRanks

Viatris shareholders elect directors and approve proposals at annual meeting - Investing.com India

Mark Cuban Takes Aim at FDA Fees - GuruFocus

Why Viatris Inc. (VIA) stock trades below fair valueJuly 2025 Pullbacks & Weekly Top Gainers Alerts - Newser

Mark Cuban calls for end to generic drug application fees to boost domestic manufacturing - Seeking Alpha

Can Viatris Inc. (VIA) stock survive global slowdownWall Street Watch & Free Daily Entry Point Trade Alerts - Newser

Can Viatris Inc. (VIA) stock surprise markets with earningsTrade Volume Summary & Low Drawdown Momentum Ideas - Newser

What is the fair value estimate for Viatris Inc. (VIA) stock in 2025Weekly Stock Analysis & AI Based Buy/Sell Signal Reports - Newser

Why Viatris Inc. (VIA) stock is a must watch tickerJuly 2025 Patterns & Risk Controlled Daily Plans - Newser

Is Viatris Inc. (VIA) stock a good hedge against inflationMarket Growth Summary & Stock Portfolio Risk Management - Newser

How Viatris Inc. stock benefits from global expansion2025 Top Gainers & High Conviction Investment Ideas - Newser

Will Viatris Inc. (VIA) stock extend growth storyMarket Risk Summary & Risk Managed Investment Strategies - Newser

How Viatris Inc. (VIA) stock compares with market leadersWeekly Stock Report & Step-by-Step Swing Trade Plans - Newser

Viatris Inc.: Revenue and Earnings Analysts Forecasts Revisions | VTRS | US92556V1061 - marketscreener.com

Viatris Inc.: Target Price Consensus and Analysts Recommendations | VTRS | US92556V1061 - marketscreener.com

Viatris Inc.: Financial Data Forecasts Estimates and Expectations | VTRS | US92556V1061 - marketscreener.com

Viatris Inc.: Dividend historical data and projections - marketscreener.com

What market sentiment indicators show for Viatris Inc. (VIA) stockJuly 2025 Big Picture & Technical Buy Zone Confirmations - Newser

Behavioral Patterns of VTRS and Institutional Flows - news.stocktradersdaily.com

Levi & Korsinsky Notifies Viatris Inc. (VTRS) Shareholders of Class Action Lawsuit and June 3, 2025 Deadline - The National Law Review

VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

How Viatris Inc. (VIA) stock trades after earningsMarket Rally & Risk Controlled Stock Pick Alerts - moha.gov.vn

Non-operating income (total) of Viatris, Inc. – SIX:VTRS - TradingView

Viatris Inc. (VIA.DE) Stock Price, News, Quote & History - Yahoo! Finance Canada

Shareholders That Lost Money on Viatris Inc. (VTRS) Should Contac - The National Law Review

These 10 S&P 500 Stocks Are Dirt Cheap This Black Friday - Benzinga

Merz Loses Bid To Block Viatris In Unified Patent Court - Law360

What Do Recent Portfolio Streamlining Moves Mean for Viatris’s True Value in 2025? - Yahoo Finance

Merz fails with PI request in first ever SPC case against Viatris - JUVE Patent

Viatris Inc Azioni (VTRS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a VTRS